Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO 2015 Dispatches: Can Expanding FDA's 'Breakthrough' Program Be An Answer To High Drug Costs?

This article was originally published in The Pink Sheet Daily

Executive Summary

America's Health Insurance Plans interim CEO Dan Durham says taking an indication-based approach, rather than the current product-specific approach, to awarding the designation would allow later-in-class products to reach market more quickly and help drive down the high cost of novel treatments approved under the expedited pathway.


Related Content

More Me-Too Drugs Please, FDA’s Jenkins Asks Industry


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts